Cite
HARVARD Citation
Kannan, K. et al. (n.d.). TAK-659, a dual SYK/FLT3 inhibitor, leads to complete and sustained tumor regression and immune memory against tumor cells upon combination with anti-PD-1 agent. European journal of cancer. pp. S92-. [Online].